Pacific Biosciences Sees FY2026 Sales $165.000M-$175.000M vs $173.371M Est
Benzinga Newsdesk 5 months ago
NewsGuidance
Pacific Biosciences (NASDAQ:PACB) sees FY2026 sales of $165.000 million-$175.000 million vs $173.371 million analyst estimate.
Pacific Biosciences (NASDAQ:PACB) sees FY2026 sales of $165.000 million-$175.000 million vs $173.371 million analyst estimate.